Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.36 |
| ▸ | CPS1 | P31327 | 2/20 | 0.36 |
| ▸ | PPIA | P62937 | 2/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16149873 | 0.89 | RXFP1 (0.40) | MAPTRXFP1CPS1TSHRHTT | |
| SCHEMBL17404612 | 0.88 | FASN (0.42) | MAPTRXFP1PPIAHTTFASN | |
| SCHEMBL17389928 | 0.81 | FASN (0.49) | MAPTRXFP1CPS1TSHRHTT | |
| SCHEMBL16150924 | 0.80 | RXFP1 (0.44) | MAPTRXFP1CPS1TSHRHTT | |
| SCHEMBL28497720 | 0.78 | CPS1 (0.39) | MAPTRXFP1CPS1TSHRHTT | |
| SCHEMBL22926299 | 0.76 | MAPT (0.41) | MAPTRXFP1CPS1TSHRHTT | |
| Hydrochloric Acid SCHEMBL17389942 | 0.75 | RXFP1 (0.43) | MAPTRXFP1CPS1 | |
| SCHEMBL21497425 | 0.73 | FASN (0.36) | MAPTRXFP1PPIAHTTNPY2R | |
| SCHEMBL16150106 | 0.70 | KMT2A (0.52) | MAPTRXFP1HTT | |
| SCHEMBL16150679 | 0.67 | FASN (0.64) | MAPTRXFP1HTTFASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| EP-3587406-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10457655-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10450286-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10399951-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190241532-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20190241533-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| EP-2968316-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20180370933-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2018-12-27 | — | — | US | disclosed |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| EP-2968316-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | Forma Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2016-01-07 | — | — | US | disclosed |
| WO-2014164749-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241533-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | MAPT 3475/4885RXFP1 4584/4885CPS1 237/4885 |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | MAPT 3475/4885RXFP1 4584/4885CPS1 237/4885 |
| US-10399951-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | MAPT 3486/4885RXFP1 4659/4885CPS1 178/4885 |
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | MAPT 3053/4885RXFP1 4617/4885CPS1 187/4885 |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | MAPT 3053/4885RXFP1 4617/4885CPS1 187/4885 |
| US-10450286-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | MAPT 3053/4885RXFP1 4617/4885CPS1 187/4885 |
| US-20180370933-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | MAPT 4100/4885RXFP1 4571/4885CPS1 207/4885 |
| US-20160002188-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | MAPT 3475/4885RXFP1 4584/4885CPS1 237/4885 |
| US-20190241532-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | MAPT 3475/4885RXFP1 4584/4885CPS1 237/4885 |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | MAPT 3475/4885RXFP1 4584/4885CPS1 237/4885 |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | MAPT 3053/4885RXFP1 4617/4885CPS1 187/4885 |
| US-10457655-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | MAPT 3053/4885RXFP1 4617/4885CPS1 187/4885 |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | MAPT 3053/4885RXFP1 4617/4885CPS1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.